Premium
A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND β‐GLUCAN PGG IN RELAPSED/REFRACTORY INDOLENT B‐CELL NON‐HODGKIN LYMPHOMA
Author(s) -
Jacobson C.A.,
Redd R.,
Reynolds C.,
Fields M.,
Armand P.,
Fisher D.C.,
Jacobsen E.D.,
LaCasce A.S.,
Bose N.,
Ottoson N.,
Freedman A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.207_2631
Subject(s) - medicine , rituximab , refractory (planetary science) , clinical endpoint , immune system , immunology , population , lymphoma , cytokine release syndrome , cancer research , oncology , t cell , clinical trial , biology , chimeric antigen receptor , environmental health , astrobiology